COSTEM 2023 | Hematopoietic stem cell boost for persistent neutropenia after CAR-T therapy
Nico Gagelmann
• 20 Oct 2023
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares some insights into a multi-center study evaluating the efficacy of hematopoietic stem cell boost (HSCB) in patients with diffuse large B-cell lymphoma (DLBCL) receiving CAR-T therapy. This study demonstrated that HSCB is a feasible approach which may be used to overcome the challenge of neutropenia and infections in these patients. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
